<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07746R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Cancer Genetics</subject><subject>Genetics and Genomics/Gene Expression</subject><subject>Oncology/Gynecological Cancers</subject><subject>Pathology/Molecular Pathology</subject></subj-group></article-categories><title-group><article-title>MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary</article-title><alt-title alt-title-type="running-head">MiRNA in Ovarian Serous Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Cheng-Han</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Subramanian</surname><given-names>Subbaya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Andrew H.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Espinosa</surname><given-names>Inigo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Senz</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Shirley X.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huntsman</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>van de Rijn</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gilks</surname><given-names>C. Blake</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pathology &#x00026; Laboratory Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, British Columbia, Canada</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, Stanford University Medical Center, Stanford, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Pathology &#x00026; Laboratory Medicine, British Columbia Cancer Agency, Vancouver, British Columbia, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Toland</surname><given-names>Amanda Ewart</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Ohio State University Medical Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>chenghan@interchange.ubc.ca</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: CHL SS DH MvdR CBG. Performed the experiments: CHL SS IE JS SZ. Analyzed the data: CHL AB JS. Contributed reagents/materials/analysis tools: DH MvdR CBG. Wrote the paper: CHL DH MvdR CBG.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>10</month><year>2009</year></pub-date><volume>4</volume><issue>10</issue><elocation-id>e7314</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>MicroRNAs (miRNA) are 20&#x0223c;25 nucleotide non-coding RNAs that inhibit the translation of targeted mRNA, and they have been implicated in the development of human malignancies. High grade serous ovarian carcinomas, the most common and lethal subtype of ovarian cancer, can occur sporadically or in the setting of BRCA1/2 syndromes. Little is known regarding the miRNA expression profiles of high grade serous carcinoma in relation to BRCA1/2 status, and compared to normal tubal epithelium, the putative tissue of origin for high grade serous carcinomas.</p></sec><sec><title>Methodology/Principal Findings</title><p>Global miRNA expression profiling was performed on a series of 33 high grade serous carcinomas, characterized with respect to BRCA1/2 status (mutation, epigenetic silencing with loss of expression or normal), and with clinical follow-up, together with 2 low grade serous carcinomas, 2 serous borderline tumors, and 3 normal fallopian tube samples, using miRNA microarrays (328 human miRNA). Unsupervised hierarchical clustering based on miRNA expression profiles showed no clear separation between the groups of carcinomas with different BRCA1/2 status. There were relatively few miRNAs that were differentially expressed between the genotypic subgroups. Comparison of 33 high grade serous carcinomas to 3 normal fallopian tube samples identified several dysregulated miRNAs (false discovery rate &#x0003c;5&#x00025;), including miR-422b and miR-34c. Quantitative RT-PCR analysis performed on selected miRNAs confirmed the pattern of differential expression shown by microarray analysis. Prognostically, lower level miR-422b and miR-34c in high grade serous carcinomas were both associated with decreased disease-specific survival by Kaplan-Meier analysis (p&#x0003c;0.05).</p></sec><sec><title>Conclusions/Significance</title><p>High grade serous ovarian carcinomas with and without BRCA1/2 abnormalities demonstrate very similar miRNA expression profiles. High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important.</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Ovarian carcinomas are the leading cause of death among tumors of the female reproductive tract and high grade serous carcinomas are the most aggressive subtype of ovarian carcinomas <xref ref-type="bibr" rid="pone.0007314-Cannistra1">&#x0005b;1&#x0005d;</xref>. High grade serous carcinomas can occur in both the familial and sporadic settings. Women with germ-line BRCA1 or BRCA2 mutation are at increased risk of developing ovarian serous carcinoma while a subset of non-familial ovarian serous carcinomas also demonstrate loss of BRCA1 through either somatic mutations or promoter methylation with transcriptional silencing <xref ref-type="bibr" rid="pone.0007314-Press1">&#x0005b;2&#x0005d;</xref>. More than half of high grade serous carcinomas overall possess some abnormality of BRCA1 or BRCA2 <xref ref-type="bibr" rid="pone.0007314-Esteller1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Pal1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Thrall1">&#x0005b;5&#x0005d;</xref>. The majority of high grade serous carcinomas also show mutation and/or loss of functional p53 <xref ref-type="bibr" rid="pone.0007314-Singer1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Kupryjanczyk1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Milner1">&#x0005b;8&#x0005d;</xref>. Though typically showing the greatest tumor burden in the ovaries, there is increasing evidence that high grade serous carcinomas originate from the epithelium of the tubal fimbriae and mullerian type epithelial inclusions of the ovary in the majority of the cases <xref ref-type="bibr" rid="pone.0007314-Crum1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Crum2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Salvador1">&#x0005b;11&#x0005d;</xref>.</p><p>MicroRNAs (miRNA) are 20&#x0223c;25 nucleotide, evolutionarily conserved, non-coding RNAs that are important in post-transcriptional gene regulation <xref ref-type="bibr" rid="pone.0007314-Gregory1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang1">&#x0005b;13&#x0005d;</xref>. By binding to the 3&#x02032; UTR region of targeted genes, miRNA can rapidly inhibit the translation of the mRNA transcript and subsequently, through formation of RNA-induced silencing complex, cause degradation of the transcript <xref ref-type="bibr" rid="pone.0007314-Gregory1">&#x0005b;12&#x0005d;</xref>. In some instances, miRNA can also promote the degradation of the targeted mRNA <xref ref-type="bibr" rid="pone.0007314-ValenciaSanchez1">&#x0005b;14&#x0005d;</xref>. This genetic regulation by miRNA is important in the fundamental processes of cell growth and differentiation. There is also emerging evidence to suggest that quantitative and qualitative (mutational) changes in miRNA and their target binding sites can promote the development and progression of tumors <xref ref-type="bibr" rid="pone.0007314-Gregory1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Calin1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Cho1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-EsquelaKerscher1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Asangani1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Shen1">&#x0005b;19&#x0005d;</xref>. miRNA profiling studies have revealed differential expression of miRNA in various carcinomas compared to their normal tissue counterparts <xref ref-type="bibr" rid="pone.0007314-Zhang1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Cho1">&#x0005b;16&#x0005d;</xref>. Some of the differentially expressed miRNA have further been linked to the repression of tumor suppressor genes or the upregulation of oncogenes at the protein product level <xref ref-type="bibr" rid="pone.0007314-Mayr1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Meng1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Sampson1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Corney1">&#x0005b;23&#x0005d;</xref>.</p><p>Recently, the miRNA expression profiles of a number of ovarian surface epithelial tumors, including high grade serous carcinomas have been described and several differentially expressed miRNAs have been identified in high grade serous carcinomas compared to normal ovarian tissue or cell lines derived from ovarian surface epithelium <xref ref-type="bibr" rid="pone.0007314-Dahiya1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Iorio1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Nam1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Yang1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang2">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Wyman1">&#x0005b;29&#x0005d;</xref>. However, a number of important questions remain unaddressed. Firstly, it is unclear whether high grade serous carcinomas with BRCA1/2 mutation differ in their miRNA expression patterns from non-mutation carrying cases; it is plausible that etiologically relevant differences in miRNA expression may be present. Secondly, with emerging evidence to suggest tubal epithelium as the tissue of origin for many high grade serous carcinomas <xref ref-type="bibr" rid="pone.0007314-Crum1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Crum2">&#x0005b;10&#x0005d;</xref>, it is likely that comparison to tubal epithelium will reveal a more representative and accurate set of dysregulated miRNA for high grade serous carcinomas, particularly given that the choice of comparator group is known to significantly influence the results of comparative gene profiling analysis <xref ref-type="bibr" rid="pone.0007314-Zorn1">&#x0005b;30&#x0005d;</xref>.</p><p>In the current study, we examined the miRNA expression profiles of 328 human miRNAs in a series of ovarian serous tumors, molecularly characterized with respect to their BRCA1/2 status, focusing on high grade serous carcinomas. Comparisons were made between subgroups with different BRCA1/2 status, to a series of normal fallopian tube samples, as well to a previously reported series of normal tissue samples and tumors of mesenchymal origin.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Clinicopathologic profiles of tumor/tissue samples</title><p>The series of ovarian serous tumors has been described previously <xref ref-type="bibr" rid="pone.0007314-Press1">&#x0005b;2&#x0005d;</xref>. These samples were extensively characterized with respect to BRCA1 and BRCA2 status with mutational and mRNA expression analysis and, in the case of BRCA1, promoter methylation and protein expression levels were also analyzed. Thirty-three high grade serous carcinomas, 2 low grade serous carcinomas and 2 serous borderline tumors, as well as 3 normal fallopian tube samples derived from the fimbriated end were included in the current analysis (<xref ref-type="table" rid="pone-0007314-t001">Table 1</xref>). The average age of the patients at the time of surgery was 62 years with a range from 39 to 85 years. The majority of the patients with high grade serous carcinoma in the current series presented with advanced-stage disease (FIGO stage III or IV). Among the 33 high grade serous carcinomas, 9 cases carry mutations in BRCA1 (8 germline and 1 somatic), 3 have mutations in BRCA2 (2 germline and 1 somatic), 10 show BRCA1 epigenetic loss (promoter methylation and decreased expression), while 11 cases show no demonstrable BRCA1 or BRCA2 loss (no mutation in BRCA1/BRCA2 and no promoter methylation with decreased BRCA1 mRNA or protein). Patient follow-up was available for all 33 cases of high grade serous carcinomas, with a median follow-up period of 3.4 years (range from 0.8 to 5.8 years). All patients with high grade serous carcinomas received combination platinum-taxane chemotherapy after surgical debulking of tumor.</p><table-wrap id="pone-0007314-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.t001</object-id><label>Table 1</label><caption><title>Summary of the clinicopathologic features of the study cases.</title></caption><alternatives><graphic id="pone-0007314-t001-1" xlink:href="pone.0007314.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">VOA</td><td align="left" rowspan="1" colspan="1">STT</td><td align="left" rowspan="1" colspan="1">Age<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">Histopathology</td><td align="left" rowspan="1" colspan="1">Grade</td><td align="left" rowspan="1" colspan="1">Stage&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">Primary site&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">BRCA1 and BRCA2 status</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">186</td><td align="left" rowspan="1" colspan="1">5035</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">223</td><td align="left" rowspan="1" colspan="1">5043</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2C</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">329</td><td align="left" rowspan="1" colspan="1">5060</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">293</td><td align="left" rowspan="1" colspan="1">5053</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Ovarian NOS</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">283</td><td align="left" rowspan="1" colspan="1">5052</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">239</td><td align="left" rowspan="1" colspan="1">5045</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">336</td><td align="left" rowspan="1" colspan="1">5064</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">327</td><td align="left" rowspan="1" colspan="1">5059</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">379</td><td align="left" rowspan="1" colspan="1">5071</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">163</td><td align="left" rowspan="1" colspan="1">5032</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA2 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">305</td><td align="left" rowspan="1" colspan="1">5055</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1A</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">BRCA2 Mutations&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">212</td><td align="left" rowspan="1" colspan="1">5038</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA2 Mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">217</td><td align="left" rowspan="1" colspan="1">5040</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">330</td><td align="left" rowspan="1" colspan="1">5061</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1C</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">332</td><td align="left" rowspan="1" colspan="1">5062</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2B</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">388</td><td align="left" rowspan="1" colspan="1">5073</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Unable to determine</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">201</td><td align="left" rowspan="1" colspan="1">5037</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">363</td><td align="left" rowspan="1" colspan="1">5068</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Omentum</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">161</td><td align="left" rowspan="1" colspan="1">5031</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2C</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">344</td><td align="left" rowspan="1" colspan="1">5066</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Right Ovary/Possible Bilateral</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">5067</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">384</td><td align="left" rowspan="1" colspan="1">5072</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Unable to determine</td><td align="left" rowspan="1" colspan="1">BRCA1 Epigenetic Loss</td></tr><tr><td align="left" rowspan="1" colspan="1">195</td><td align="left" rowspan="1" colspan="1">5036</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2C</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">236</td><td align="left" rowspan="1" colspan="1">5044</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">280</td><td align="left" rowspan="1" colspan="1">5050</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">172</td><td align="left" rowspan="1" colspan="1">5033</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Right Ovary</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">5048</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">319</td><td align="left" rowspan="1" colspan="1">5057</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">372</td><td align="left" rowspan="1" colspan="1">5070</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">240</td><td align="left" rowspan="1" colspan="1">5046</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">297</td><td align="left" rowspan="1" colspan="1">5054</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">366</td><td align="left" rowspan="1" colspan="1">5069</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">Serous carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">273</td><td align="left" rowspan="1" colspan="1">5049</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">Serous/undifferentiated carcinoma</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">221</td><td align="left" rowspan="1" colspan="1">5042</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">Low-grade papillary serous carcinoma</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">324</td><td align="left" rowspan="1" colspan="1">5058</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">Low-grade papillary serous carcinoma</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3C</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">No BRCA1/2 abnormalities</td></tr><tr><td align="left" rowspan="1" colspan="1">277</td><td align="left" rowspan="1" colspan="1">5132</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">Serous borderline tumor</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">1B</td><td align="left" rowspan="1" colspan="1">Left Ovary</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">278</td><td align="left" rowspan="1" colspan="1">5133</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">Serous borderline tumor</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">3B</td><td align="left" rowspan="1" colspan="1">Bilateral Ovaries</td><td align="left" rowspan="1" colspan="1">ND</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>Age at the time of surgery; &#x0002a;&#x0002a;FIGO staging system; &#x0002a;&#x0002a;&#x0002a;&#x0201c;Primary site&#x0201d; refers to the site of the dominant tumor mass, if there was one, at the time of surgery; &#x02020;Germline mutation; VOA, Vancouver tumor bank number; STT, Stanford tumor bank number; NA, not applicable; ND, not done.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Hierarchical clustering based on microRNA expression profiles</title><p>To better appreciate the miRNA expression signature of ovarian serous tumors, miRNA expression of the 37 ovarian serous tumors and 3 normal fallopian tube samples in our current series were analyzed together with the miRNA expression from a previously reported series of soft tissue tumors and non-neoplastic soft tissue samples <xref ref-type="bibr" rid="pone.0007314-Subramanian1">&#x0005b;31&#x0005d;</xref>. Unsupervised hierarchical clustering based on 61 stringently filtered human miRNA showed a clear separation between ovarian serous tumors, normal fallopian tubes and soft tissue tumor/normal muscle samples (<xref ref-type="fig" rid="pone-0007314-g001">Figure 1</xref>). The complete filtered dataset is available in <xref ref-type="supplementary-material" rid="pone.0007314.s001">Table S1</xref>. Ovarian serous tumors, as a group, showed upregulation of a group of 21 miRNA illustrated by the heatmap in <xref ref-type="fig" rid="pone-0007314-g001">Figure 1</xref> (highlighted in blue). Among this cluster of 21 miRNA, miR-200c, miR-141 and miR-203 were previously reported to be expressed at relatively high levels in tissues of the male and female reproductive system <xref ref-type="bibr" rid="pone.0007314-Landgraf1">&#x0005b;32&#x0005d;</xref>. In comparison, soft tissue tumors and non-neoplastic muscle tissues showed uniformly higher level expression of miR-517a and miR-517b (highlighted in red in <xref ref-type="fig" rid="pone-0007314-g001">Figure 1</xref>). The 3 normal fallopian tube samples clustered closely together and showed a highly uniform miRNA expression profile that is distinct from that of either ovarian carcinomas or the soft tissue tumors. No apparent separation between high grade ovarian serous carcinomas of different BRCA1/2 status was noted.</p><fig id="pone-0007314-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.g001</object-id><label>Figure 1</label><caption><title>Unsupervised hierarchical clustering of 37 ovarian serous tumors, 3 normal fallopian tube and 34 soft tissue tumor/normal muscle samples based on the miRNA expression profiles of the 60 filtered human miRNA.</title><p>&#x0002a; BRCA1 epigenetic loss; &#x0002a;&#x0002a; BRCA1 mutation; &#x0002a;&#x0002a;&#x0002a; BRCA2 mutation; SS, synovial sarcoma; LMS, leiomyosarcoma; GIST, gastrointestinal stromal tumor; ARMS, alveolar rhabdomyosarcomas; PRMS, pleomorphic rhabdomyosarcomas; ERMS, embryonal rhabdomyosarcomas.</p></caption><graphic xlink:href="pone.0007314.g001"/></fig></sec><sec id="s2c"><title>High grade ovarian serous carcinomas of different BRCA1/2 status</title><p>For the comparative analysis between high grade serous carcinomas of different BRCA1/2 status, a less stringent set of gene filtering criteria was employed for the 37 serous tumors and 3 fallopian tube samples in an attempt to identify miRNA showing more subtle variation that may be of biologic interest. A total of 80 miRNA passed the filtering criteria and the complete filtered dataset is available in <xref ref-type="supplementary-material" rid="pone.0007314.s002">Table S2</xref>, with the accompanying unsupervised hierarchical clustering dendrogram depicted in <xref ref-type="fig" rid="pone-0007314-g002">Figure 2</xref>. While the 3 fallopian tube samples and 3 of the 4 serous borderline tumors/low grade serous carcinoma samples clustered together, there was again no apparent separation seen among the high grade ovarian serous carcinomas with respect to BRCA1/2 status or tumor stage. Significance analysis of microarrays (SAM) was performed to identify differences in miRNA expression between groups of high grade serous carcinomas with mutations in BRCA1, with mutations in BRCA2, with BRCA1 epigenetic loss and with no demonstrable BRCA1 or BRCA2 loss. Very few miRNA were found to be differentially expressed with a false-discovery rate (FDR) &#x0003c;5&#x00025; between the BRCA1/2 subgroups (<xref ref-type="table" rid="pone-0007314-t002">Table 2</xref>). Increased expression of miR-29a and miR-29b was seen in the combined group of carcinomas with any demonstrable BRCA1/2 loss compared to the group with no demonstrable BRCA1/2 abnormalities. A list of predicted target genes of miR-29a, miR-29b and miR-214 (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">www.targetscan.org/</ext-link>) is shown in <xref ref-type="supplementary-material" rid="pone.0007314.s003">Table S3</xref> and it includes known tumor suppressors such as PTEN, a putative target of miR-29a. BRCA1 and BRCA2 were not among the predicted targets of miR-29a, miR-29b or miR-214.</p><fig id="pone-0007314-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.g002</object-id><label>Figure 2</label><caption><title>Unsupervised hierarchical clustering of 37 ovarian serous tumors and 3 normal fallopian tubes based on the miRNA expression profiles of the 80 filtered human miRNA.</title><p>&#x0002a; BRCA1 epigenetic loss; &#x0002a;&#x0002a; BRCA1 mutation; &#x0002a;&#x0002a;&#x0002a; BRCA2 mutation.</p></caption><graphic xlink:href="pone.0007314.g002"/></fig><table-wrap id="pone-0007314-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.t002</object-id><label>Table 2</label><caption><title>Summary of the SAM analysis comparing miRNA expression profiles between high grade serous carcinomas of different BRCA1/2 status and between ovarian tumors of different histopathologic types, with a false-discovery rate (FDR) &#x0003c;5&#x00025; (miRNA in bold italic are associated with a FDR &#x0003c;0.1&#x00025;).</title></caption><alternatives><graphic id="pone-0007314-t002-2" xlink:href="pone.0007314.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Tumor type</td><td align="left" rowspan="1" colspan="1">Tumor type compared to</td><td align="left" rowspan="1" colspan="1">Upregulated miRNA</td><td align="left" rowspan="1" colspan="1">Downregulated miRNA</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>High grade serous carcinoma</bold></td><td align="left" rowspan="1" colspan="1"><bold>Fallopian tube</bold></td><td align="left" rowspan="1" colspan="1"><bold>19</bold> (<italic>miR-200c, miR-106b, miR-141, miR-106a, miR-17-5p, miR-107, miR-20b, miR-181b, miR-146b, miR-103, miR-205, miR-182, miR-203, miR-20a, miR-15a, miR-422b, miR-21, miR-363, miR-422a</italic>)</td><td align="left" rowspan="1" colspan="1"><bold>9</bold> (<bold><italic>miR-145, miR-143, miR-34c, miR-195, miR-29c, miR-125b, let-7b</italic></bold><italic>, miR-126, let-7c</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>High grade serous carcinoma</bold></td><td align="left" rowspan="1" colspan="1"><bold>Low grade serous carcinoma/serous borderline tumor</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>12</bold> (<bold><italic>miR-34b, miR-34c, miR-449, miR-509, miR-508, miR-34a, miR-92, miR-514, miR-29a, let-7b, miR-10a, miR-29c</italic></bold>)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Low grade serous carcinoma/serous borderline tumor</bold></td><td align="left" rowspan="1" colspan="1"><bold>Fallopian tube</bold></td><td align="left" rowspan="1" colspan="1"><bold>39</bold> (<bold><italic>miR-200c, miR-141, miR-20b, miR-20a, miR-106a, miR-16, miR-17-5p, miR-34a, miR-422b, miR-509, miR-449, miR-30b, miR-92, miR-15a, miR-422a, miR-107, miR-221, miR-30d, miR-103, miR-146b, miR-30a-5p, miR-15b, miR-30e-5p, miR-508, miR-514, miR-106b, miR-200b, miR-21, miR-30c, miR-29a, miR-200a, miR-377, miR-34b, miR-205, miR-224, miR-181b, let-7g</italic></bold><italic>, miR-222, miR-10a</italic>)</td><td align="left" rowspan="1" colspan="1"><bold>13</bold> (<bold><italic>miR-145, miR-143, miR-126, miR-100, miR-152</italic></bold><italic>, miR-214, miR-125b, miR-99a, miR-195, miR-29c, miR-451, miR-342, let-7b</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 or BRCA2 loss (any)</bold></td><td align="left" rowspan="1" colspan="1"><bold>No BRCA1 loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>2</bold> (<bold><italic>miR-29a miR-29b</italic></bold>)</td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 loss (any)</bold></td><td align="left" rowspan="1" colspan="1"><bold>No BRCA1 loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>1</bold> (<bold><italic>miR-214</italic></bold>)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 mutation</bold></td><td align="left" rowspan="1" colspan="1"><bold>No BRCA1 loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 mutation</bold></td><td align="left" rowspan="1" colspan="1"><bold>BRCA2 mutation</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 mutation</bold></td><td align="left" rowspan="1" colspan="1"><bold>BRCA1 epigenetic loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BRCA1 epigenetic loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>No BRCA1 loss</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1"><bold>0</bold></td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2d"><title>High grade ovarian serous carcinomas versus Normal fallopian tubes</title><p>Given that a significant proportion of high grade ovarian serous carcinomas are currently believed to be derived from the tubal epithelium, a comparison was made between high grade serous carcinomas and normal fallopian tube, sampled from the fimbriated end. The fimbriated end of the fallopian tube is the site where primary tubal carcinoma occurs in BRCA mutation carriers <xref ref-type="bibr" rid="pone.0007314-Crum1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Crum2">&#x0005b;10&#x0005d;</xref>. The use of tissue from the fimbriated end of the fallopian tube was also done to increase the representation of the epithelial elements while minimizing the presence of mesenchymal elements, as epithelial cells predominate in this region of the tube. Even though only 3 fallopian tube samples were included in the current study, they exhibited highly similar patterns of miRNA expression that is likely an accurate reflection of the miRNA levels in the fallopian tube. SAM comparison of the 33 high grade serous carcinomas to the 3 normal fallopian tubes identified 19 upregulated miRNA and 9 downregulated miRNA with a FDR &#x0003c;5&#x00025; (<xref ref-type="table" rid="pone-0007314-t002">Table 2</xref>). While all 9 downregulated miRNA identified in our current study have been previously reported to be downregulated in ovarian carcinomas in series composed predominantly or exclusively of serous carcinomas compared to normal ovarian tissue/normal ovarian surface epithelial cell lines, only 8 of the 19 upregulated miRNA identified in our current study have been reported in these prior comparisons (<xref ref-type="supplementary-material" rid="pone.0007314.s004">Table S4</xref>) <xref ref-type="bibr" rid="pone.0007314-Dahiya1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Iorio1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Nam1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Yang1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang2">&#x0005b;28&#x0005d;</xref>.</p></sec><sec id="s2e"><title>Low grade serous carcinoma/serous borderline tumors</title><p>In comparison to normal fallopian tubes, low grade serous carcinomas and serous borderline tumors as a group showed significant upregulation of 39 miRNA and downregulation of 13 miRNA with a FDR &#x0003c;5&#x00025; (<xref ref-type="table" rid="pone-0007314-t002">Table 2</xref>). Low grade serous carcinomas and serous borderline tumors were grouped together in our current analysis because they are regarded as biologically closely-related entities <xref ref-type="bibr" rid="pone.0007314-Singer1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-ShihIe1">&#x0005b;33&#x0005d;</xref>. Comparison between high grade serous carcinomas and low grade serous carcinomas/serous borderline tumors revealed 12 miRNA that were more highly expressed in low grade serous carcinomas/serous borderline tumors with a FDR &#x0003c;5&#x00025; (<xref ref-type="table" rid="pone-0007314-t002">Table 2</xref>).</p></sec><sec id="s2f"><title>Validation of the miRNA expression patterns by quantitative RT-PCR</title><p>Quantitative RT-PCR (qRT-PCR) analysis was performed for selected miRNA (miR-34c, miR-143, miR-145, miR-29a and miR-29b) on the same series of high grade serous carcinoma and normal fallopian tube samples, and the findings are depicted in <xref ref-type="fig" rid="pone-0007314-g003">Figure 3</xref>. In accordance with the microarray data, miR-34c, miR-143 and miR-145 showed significant downregulation in high grade serous carcinomas compared to normal fallopian tubes by qRT-PCR analysis. Similarly, among high grade serous carcinomas, the expression of miR-29a and miR-29b were also significantly higher in group with BRCA1/2 abnormalities compared to group lacking demonstrable BRCA1/2 abnormalities. These qRT-PCR findings support the microarray observations overall.</p><fig id="pone-0007314-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.g003</object-id><label>Figure 3</label><caption><title>qRT-PCR analysis of the expression of selected miRNAs in high grade serous carcinomas (HG serous ca) and normal fallopian, with the average expression values (&#x000b1; standard errors) depicted.</title><p>A) miR-34c expression levels for 32 high grade serous carcinomas (HG serous ca) and 3 fallopian tubes (sample STT5049 was not included in the analysis due to insufficient material). B) miR-143 expression levels for 29 high grade serous carcinomas and 3 fallopian tubes (samples STT5036/5048/5049/5050 were not included in the analysis due to insufficient material). C) miR-145 expression levels for 29 high grade serous carcinomas and 3 fallopian tubes (samples STT5036/5048/5049/5050 were not included in the analysis due to insufficient material). D) miR-29a expression levels for 32 high grade serous carcinomas and 3 fallopian tubes (sample STT5049 was not included in the analysis due to insufficient material). E) miR-29b expression levels for 32 high grade serous carcinomas and 3 fallopian tubes (sample STT5049 was not included in the analysis due to insufficient material).</p></caption><graphic xlink:href="pone.0007314.g003"/></fig></sec><sec id="s2g"><title>Prognostic significance of miR-34c and miR-422b high grade ovarian serous carcinomas</title><p>Follow-up data on disease-specific survival were available for all 33 cases of high grade serous carcinomas, with a median follow-up period of 3.4 years (range from 0.8 to 5.8 years). Because of the relatively short period of follow-up for some of the cases in the current series, we examined both recurrence-free survival and disease-specific survival to identify prognostically important miRNAs. Multivariate Cox regression analysis was performed on the less stringently filtered dataset. miR-34c was found to be the sole independent predictor of recurrence-free survival (HR&#x0200a;&#x0003d;&#x0200a;0.29, 95&#x00025; CI&#x0200a;&#x0003d;&#x0200a;0.10&#x02013;0.84; p&#x0200a;&#x0003d;&#x0200a;0.02) and miR-422b was found to be the sole independent predictor of disease-specific survival (HR&#x0200a;&#x0003d;&#x0200a;0.21, 95&#x00025; CI&#x0200a;&#x0003d;&#x0200a;0.08&#x02013;0.53; p&#x0200a;&#x0003d;&#x0200a;0.001). Both miR-34c and miR-422b were also among the miRNAs found to be significantly dysregulated in high grade serous carcinomas compared to fallopian tubes (<xref ref-type="table" rid="pone-0007314-t002">Table 2</xref>).</p><p>Using the median expression values for miR-34c and miR-422b as respective cutoffs, high grade serous carcinomas were separated into high-expression group (expression values &#x0003e; median value) and low-expression group (expression values &#x02264; median value) for Kaplan-Meier survival analysis (<xref ref-type="fig" rid="pone-0007314-g004">Figure 4</xref>). Based on microarray-derived expression values, the group with lower level miR-34c expression had decreased recurrence survival (p&#x0200a;&#x0003d;&#x0200a;0.049) and decreased disease-specific survival (p&#x0200a;&#x0003d;&#x0200a;0.019) compared to the group with higher level miR-34c expression. For miR-422b, the group with lower level miR-422b expression was also associated with decreased disease-specific survival (p&#x0200a;&#x0003d;&#x0200a;0.032). When qRT-PCR derived expression values were used for miR-34c, a similar trend between decreased miR-34c expression and decreased disease-specific survival was seen though statistical significance was not reached (p&#x0200a;&#x0003d;&#x0200a;0.06). There was no statistically significant correlation between the levels of miR-34c or miR-422b and the initial tumor stages.</p><fig id="pone-0007314-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007314.g004</object-id><label>Figure 4</label><caption><title>Kaplan-Meier survival analysis for high grade serous carcinomas stratified into low-expression group (&#x02264; median expression value, indicated by dashed line) and high-expression group (&#x0003e; median expression value, indicated by solid line).</title><p>A) Kaplan-Meier survival curves for low miR-422b level group (dashed line) and high miR-422b level group (solid line) based on microarray analysis, B) Kaplan-Meier survival curves for low miR-34c level group (dashed line) and high miR-34c level group (solid line) based on microarray analysis, C) Kaplan-Meier survival curves for low miR-34c level group (dashed line) and high miR-34c level group (solid line) based on qRT-PCR analysis.</p></caption><graphic xlink:href="pone.0007314.g004"/></fig><p>Because of the known functional link between p53 and miR-34c <xref ref-type="bibr" rid="pone.0007314-Corney2">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-He1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Hermeking1">&#x0005b;36&#x0005d;</xref>, p53 mutation status was assessed and interpretable data was available for 20 of the 33 high grade serous carcinomas. 17 of the 20 cases of high grade serous carcinomas demonstrated p53 mutation with 11 missense mutation, 3 frame-shift mutation, 2 in frame deletion and one intronic deletion (<xref ref-type="supplementary-material" rid="pone.0007314.s005">Table S5</xref>). There was no significant difference in miR-34c levels between mutation-positive and mutation-negative tumors by either microarray or qRT-PCR analyses.</p></sec></sec><sec id="s3"><title>Discussion</title><p>miRNA are non-coding RNA that play important roles in post-transcriptional regulation. During oncogenesis, dysregulated or dysfunctional miRNA can result in increased translation of oncoprotein(s) and/or decreased translation of tumor suppressor protein(s). In the current study, we used a previously validated microarray-based methodology <xref ref-type="bibr" rid="pone.0007314-Subramanian1">&#x0005b;31&#x0005d;</xref> to evaluate the expression levels of 328 human miRNA in a series of extensively characterized ovarian surface epithelial tumors and normal fallopian tube samples. Several biologically important patterns and correlations emerged from our analysis of the data. Ovarian surface epithelial tumors as a group possessed a miRNA expression profile that was highly dissimilar to the miRNA expression profiles of soft tissue tumors. Given the documented roles of miRNA in cellular differentiation <xref ref-type="bibr" rid="pone.0007314-Landgraf1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Lu1">&#x0005b;37&#x0005d;</xref>, some of these observed differences likely relate to underlying differences in differentiation into different cellular lineages, i.e. epithelial versus mesenchymal.</p><p>While a number of recent studies have characterized the expression profiles of miRNA in ovarian carcinomas including high grade serous carcinomas, none has examined the miRNA levels of high grade serous carcinomas with differing BRCA1/2 abnormalities. BRCA1 or BRCA2 abnormalities are present in most high grade serous carcinomas and lead to chromosomal instability through loss of the ability to repair double strand breaks by homologous recombination <xref ref-type="bibr" rid="pone.0007314-Kobel1">&#x0005b;38&#x0005d;</xref>. In the current study, miR-29a and miR-29b were found to be more highly upregulated in high grade serous carcinomas with any demonstrable BRCA1/2 loss compared to the group lacking demonstrable BRCA1/2 abnormalities by both microarray and qRT-PCR analyses. Notably, high grade serous carcinomas carrying BRCA1 mutation were previously reported by us to possess lower PTEN mRNA levels <xref ref-type="bibr" rid="pone.0007314-Press1">&#x0005b;2&#x0005d;</xref>, and PTEN is a among the top 20 predicted targets of miR-29a. It is plausible that the high level of miR-29a may cause increased degradation of PTEN mRNA, resulting in the decreased level of PTEN mRNA observed in this group of tumors. It is important to note that only a small number of BRCA2 mutation-carrying tumors was included in this series and our analysis will likely not reveal subtle differences in this group compared to other groups. Overall, very few differences were observed in the comparisons between high grade serous carcinomas possessing mutation in BRCA1, mutation in BRCA2, epigenetic silencing of BRCA1, and no demonstrable loss in BRCA1. It is possible that all of the tumors reach the same endpoint during oncogenesis (i.e. chromosomal instability), despite the presence of different underlying molecular abnormalities. The near identical miRNA expression profiles between the genotypic subgroups may then reflect this end state.</p><p>All of the ovarian carcinoma miRNA profiling analysis reported to date have used non-neoplastic ovarian tissue samples and/or cultured ovarian surface epithelial cells for comparison as normal tissue counterpart <xref ref-type="bibr" rid="pone.0007314-Dahiya1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Iorio1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Nam1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Yang1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang2">&#x0005b;28&#x0005d;</xref>. There is increasing evidence to suggest most high-grade serous carcinomas, including those with bulky unilateral or bilateral ovarian disease, do in fact arise from the tubal fimbriae or secondary mullerian epithelial inclusions in the ovaries <xref ref-type="bibr" rid="pone.0007314-Crum1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Crum2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Salvador1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Dubeau1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Folkins1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Levanon1">&#x0005b;41&#x0005d;</xref>. In patients with familial BRCA1/2 mutation, intraepithelial carcinoma at the tubal fimbriae represents the most common earliest evidence of neoplasm in prophylactic bilateral salpingooophrectomy specimens <xref ref-type="bibr" rid="pone.0007314-Hirst1">&#x0005b;42&#x0005d;</xref>, whereas analogous precursor lesion on ovarian surface has not been consistently demonstrated despite careful examination. In sporadic cases of ovarian serous carcinomas, there is frequently evidence of similar appearing intraepithelial carcinoma involving the tubal fimbriae, though in these cases (and the cases included in this study), one cannot be certain whether the tubal neoplasm represents the primary site of the disease or site of secondary involvement <xref ref-type="bibr" rid="pone.0007314-Kindelberger1">&#x0005b;43&#x0005d;</xref>. Furthermore, the immunophenotypic profile of high grade ovarian serous carcinomas appears to more closely resemble that of normal tubal epithelium than ovarian surface epithelium <xref ref-type="bibr" rid="pone.0007314-Tong1">&#x0005b;44&#x0005d;</xref>. Given that mullerian type epithelium from the tubal fimbriae or ovarian mullerian inclusions is now regarded as the more likely epithelium of origin for high grade ovarian serous carcinomas, we believe that the use of tubal fimbriae as normal tissue counterpart for comparison is most appropriate. Moreover, high grade serous carcinomas generally are composed predominantly of neoplastic epithelium with relatively little stroma. Comparison to normal ovarian tissue, which contains an overwhelming predominance of stromal tissue is likely not an ideal comparison. The use of cultured ovarian surface epithelial cells for comparison may also be problematic as it would require an assumption that the miRNA expression profiles of normal ovarian surface epithelial cells are unaltered in culture. Although only three samples of normal fallopian tube tissue were analyzed, they showed highly uniform expression profiles, leading us to conclude that analysis of additional samples would be non-contributory.</p><p>In the current study a total of 28 differentially expressed miRNA were identified with 19 miRNA being upregulated and 9 miRNA being downregulated in high grade serous carcinoma versus normal fallopian tubes by microarray analysis. Selected dysregulated miRNA identified by microarray analysis were also confirmed to be dysregulated by qRT-PCR analysis. Nine of the 19 upregulated miRNA and all 9 downregulated miRNA were reported to be dysregulated in the same manner in earlier analyses <xref ref-type="bibr" rid="pone.0007314-Dahiya1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Iorio1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Nam1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Yang1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Zhang2">&#x0005b;28&#x0005d;</xref>. miR-145 and/or miR-143, the most significantly downregulated miRNA found in the current analysis were also frequently observed to be downregulated in carcinomas of prostate, colon, and breast, relative to the respective normal tissue <xref ref-type="bibr" rid="pone.0007314-Bandres1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Iorio2">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Michael1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Ozen1">&#x0005b;48&#x0005d;</xref> and in B-cell malignancies <xref ref-type="bibr" rid="pone.0007314-Akao1">&#x0005b;49&#x0005d;</xref>. In addition, low grade serous carcinomas and serous borderline tumor also demonstrated similarly low levels of miR-145 and miR-143 in the current series. It is important to note that when the precursor or mature form of miR-145 were transfected into colon cancer and Burkitt lymphoma cell lines, dose-dependent growth inhibition was observed <xref ref-type="bibr" rid="pone.0007314-Akao1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Akao2">&#x0005b;50&#x0005d;</xref>. miR-145 and miR-143 in these instances appear to function as a tumor suppressor and similar tumor suppressor roles for these miRNA may be speculated in the case of high grade serous carcinomas and serous borderline tumors/low grade serous carcinomas. The absence of upregulated miRNA in high grade serous versus serous borderline tumor/low grade serous carcinoma parallel the findings made when mRNA expression profiles were compared between these groups <xref ref-type="bibr" rid="pone.0007314-Gilks1">&#x0005b;51&#x0005d;</xref>. A possible explanation includes the rapid divergence of chromosomally unstable high grade serous carcinomas after the early events during oncogenesis (typically loss of BRCA1 or BRCA2 and p53 loss) that results in heterogeneity within this group of tumors, such that no consistent pattern of miRNA upregulation emerged across the group as a whole, compared to the low grade tumors.</p><p>Prognostically, the level of miR-422b and the level of miR-34c were both found to be positive predictors of patient survival by microarray analysis. miR-422b was among the 19 miRNA that were found to be significantly upregulated in high grade serous carcinomas compared to normal fallopian tubes. Little is known about the functional importance of miR-422b at the present. miR-34c was among the 9 miRNA that were found to be downregulated in high grade serous carcinomas compared to fallopian tubes and high grade serous carcinomas with greater downregulation of miR-34c were associated with more aggressive clinical behavior. These findings point to a tumor suppressor role for miR-34c in high grade serous carcinomas. Functionally, miR-34c expression is known to be regulated by p53 and low level of miR-34c was observed in p53 deficient ovarian carcinoma cell lines <xref ref-type="bibr" rid="pone.0007314-Corney2">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-He1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-He2">&#x0005b;52&#x0005d;</xref>. Mutation of p53 is common in high grade ovarian serous carcinomas, occurring in about 80&#x00025; of cases based on the literature <xref ref-type="bibr" rid="pone.0007314-ShihIe1">&#x0005b;33&#x0005d;</xref> and in the current series (85&#x00025;), while low grade ovarian serous carcinomas and serous borderline tumors typically do not possess p53 mutation <xref ref-type="bibr" rid="pone.0007314-Singer1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-ONeill1">&#x0005b;53&#x0005d;</xref>. However, the lack of significant association between miR-34c downregulation and p53 mutation in our current series indicate that additional influences are likely important in regulating miR-34c expression in high grade serous carcinomas.</p><p>With regard to the prognostic significance of miR-34c, analysis based on the microarray data demonstrated significant association between low-level miR-34c expression and decreased disease-specific survival, while analysis based on qRT-PCR data showed a similar trend but did not reach statistical significance with a p-value of 0.06. Because the input miRNA samples for both microarray and qRT-PCR analysis were derived from the same extraction batch, the observed discrepancies likely reflect differences in methodology. A number of studies/reviews have addressed the issues of reproducibility between microarray and qRT-PCR quantification <xref ref-type="bibr" rid="pone.0007314-Chuaqui1">&#x0005b;54&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Etienne1">&#x0005b;55&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Morey1">&#x0005b;56&#x0005d;</xref>; while there is in general a good correlation between microarray and qRT-PCR data, there is some variability and the correlation is not perfect. In this study, the downregulation of miR-34c in high grade serous carcinomas shown by microarray analysis was confirmed by qRT-PCR analysis but inter-method variability appears to have affected the reproducibility of demonstration of a statistically significant miR-34c prognostic association, indicating borderline prognostic significance, based on this cohort. Further study will be needed to verify the prognostic significance of miR-34c downregulation in high grade serous carcinoma.</p><p>In summary, miRNA expression analysis of the current series of ovarian serous tumors and normal fallopian tubes has provided us with several important insights. High grade serous carcinomas of different BRCA1/2 status exhibit highly similar miRNA expression patterns, with very few differences present. Comparison between high grade serous carcinomas and normal tubal epithelium revealed several dysregulated miRNA, including miR-34c and miR-422b, the levels of which are both associated with prognostic importance in our current series. This improved understanding of the pattern and the significance of miRNA dysregulation in high grade serous carcinoma will allow us to better understand the oncobiology of this aggressive disease.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Patient tissue sample collection</title><p>Forty fresh frozen tumor/tissue samples were obtained from surgical specimens resected at Vancouver General Hospital (Vancouver, BC, Canada) from 2003 to 2006 with consent from the patients. This study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the institutional ethics review board at The University of British Columbia (H02-61375 and R05&#x02013;0119). All patients provided written informed consent for the collection of samples and subsequent analysis. The 40 samples include 33 high grade serous carcinomas, 2 low grade serous carcinomas, 2 serous borderline tumors and 3 normal fallopian tubes. Detailed clinicopathologic features for the ovarian surface epithelial tumors were published previously <xref ref-type="bibr" rid="pone.0007314-Press1">&#x0005b;2&#x0005d;</xref>. The clinicopathologic features and miRNA expression data from the 34 soft tissue tumor and tissue samples included for selected comparison were reported previously <xref ref-type="bibr" rid="pone.0007314-Subramanian1">&#x0005b;31&#x0005d;</xref>.</p></sec><sec id="s4b"><title>microRNA extraction and microRNA microarray study</title><p>The details of miRNA extraction and microarray analysis were published previously <xref ref-type="bibr" rid="pone.0007314-Subramanian1">&#x0005b;31&#x0005d;</xref>. Briefly, frozen sections of the tumor/tissue samples were performed to confirm the presence of specified tumor/tissue types. The same frozen tumor samples were used to isolate total RNA using mirVanaTM RNA isolation kit (Ambion, Austin, TX, USA). Reference RNA (XpressRef Universal Total RNA) was obtained from Super-Array (Frederick, MD, USA). The microarrays contained a total of 668 probes spotted in duplicate, representing 328 known human miRNAs, 113 mouse miRNAs, 45 rat miRNAs, 154 predicted human miRNAs and 28 control probes (Ambion, Austin, TX, USA). After separating the miRNA fraction from 25 ug of total RNA, miRNA from reference and tissue samples were tailed and indirectly labeled using Cy3 and Cy5 amine reactive dyes respectively (Amersham Biosciences, Buckinghamshire, UK) using mirVana miRNA labeling kit (Ambion, Austin, TX, USA). Hybridization was carried out at 42&#x000b0;C for 12&#x02013;16 hrs. The arrays were washed and immediately scanned using GenePiX 4000B array scanner (Axon Instruments, Foster City, CA, USA) and fluorescence ratios (tumor/reference) were calculated using GenePix software.</p></sec><sec id="s4c"><title>Analysis of microarray data</title><p>The arrays were gridded using the GenePix program and normalized images and data were uploaded to SMD where complete raw data of all miRNA microarrays used in this study can be found (<ext-link ext-link-type="uri" xlink:href="http://genome-www5.stanford.edu/">http://genome-www5.stanford.edu/</ext-link>) <xref ref-type="bibr" rid="pone.0007314-Sherlock1">&#x0005b;57&#x0005d;</xref>. Control and empty spots on the arrays were not included for analysis, and spots flagged as bad spots on visual inspection of the arrays were also excluded. Only miRNA spots with a ratio of signal over background of at least 1.5 in both the Cy3 and Cy5 channel, and with at least 80&#x00025; good data were included. For the combined analysis of ovarian surface epithelial tumors and soft tissue tumors, miRNAs were filtered retaining only those whose expression levels differed by at least 9-fold in at least 3 samples, and for the analysis of ovarian surface epithelial tumors and normal fallopian tubes, miRNAs were filtered retaining only those whose expression levels differed by at least 4-fold in at least 2 samples.</p></sec><sec id="s4d"><title>qRT-PCR miRNA analysis</title><p>Quantitative RT-PCR analysis of miR-34c, miR-143, miR-145, miR-29a and miR-29b was performed on the current series of high grade serous carcinomas and fallopian tube samples, using the same extracted total RNA used for the microarray analysis. cDNA was reverse transcribed from individual total RNA samples (10 ng input RNA) using TagMan MicroRNA Assays (Applied Biosystems, USA) with miRNA specific primer and TagMan MicroRNA Reverse Transcription Kit (Applied Biosystems, USA). A separate reverse transcription was perfomed for endogenous control (18S ribosomal RNA) using the SuperScript III First-Strand Synthesis System (Invitrogen, USA). PCR products were amplified from the cDNA samples using MicroRNA Assays and TagMan Universal PCR Master Mix (Applied Biosystems, USA). The levels of the endogenous control were used to normalize the expression levels of each miRNA. The expression values depicted represent ratios between the normalized level of individual sample and fallopian tube sample STT5136.</p></sec><sec id="s4e"><title>P53 mutation analysis</title><p>All high grade serous carcinoma samples were screened for p53 mutation with exons 5 to 8 analyzed by direct sequencing in both sense and antisense directions using the BigDye Terminator Cycle Sequencing 3.1 Kit (Applied Biosystems). The sequencing reactions were carried out according to the manufacturer's instructions.</p></sec><sec id="s4f"><title>Statistics</title><p>Unsupervised hierarchical clustering analysis and significance analysis of microarrays (SAM) were then performed as described previously <xref ref-type="bibr" rid="pone.0007314-Eisen1">&#x0005b;58&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Tusher1">&#x0005b;59&#x0005d;</xref>. For SAM analysis, a false-discovery rate (FDR) of less than 5&#x00025; was considered significant in the current study. Multivariate Cox regression analysis and Kaplan-Meier log-rank method were used for survival data analysis using SPSS software (SPSS, Chicago, IL, USA). TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org">www.targetscan.org</ext-link>) release 4.2 was used to identify predicted miRNA targets <xref ref-type="bibr" rid="pone.0007314-Lewis1">&#x0005b;60&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007314-Grimson1">&#x0005b;61&#x0005d;</xref>.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0007314.s001"><label>Table S1</label><caption><p>Dataset containing the expression values for 60 filtered human miRNA in ovarian surface serous tumor, normal fallopian tube and soft tissue tumor/normal muscle samples.</p><p>(0.09 MB XLS)</p></caption><media xlink:href="pone.0007314.s001.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007314.s002"><label>Table S2</label><caption><p>Dataset containing the expression values for 80 filtered human miRNA in ovarian serous tumor and normal fallopian tube samples.</p><p>(0.07 MB XLS)</p></caption><media xlink:href="pone.0007314.s002.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007314.s003"><label>Table S3</label><caption><p>Predicted target genes of miR-29a, miR-29b and miR-214 (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">www.targetscan.org/</ext-link>).</p><p>(0.12 MB XLS)</p></caption><media xlink:href="pone.0007314.s003.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007314.s004"><label>Table S4</label><caption><p>Comparison of the miRNA profiling analysis results between prior studies and the current study.</p><p>(0.03 MB XLS)</p></caption><media xlink:href="pone.0007314.s004.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007314.s005"><label>Table S5</label><caption><p>Summary results of p53 mutation analysis findings in high grade serous carcinomas.</p><p>(0.03 MB XLS)</p></caption><media xlink:href="pone.0007314.s005.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0007314-Cannistra1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannistra</surname><given-names>SA</given-names></name></person-group><year>2004</year><article-title>Cancer of the ovary.</article-title><source>N Engl J Med</source><volume>351</volume><fpage>2519</fpage><lpage>2529</lpage><pub-id pub-id-type="pmid">15590954</pub-id></mixed-citation></ref><ref id="pone.0007314-Press1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Press</surname><given-names>JZ</given-names></name><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>Young</surname><given-names>S</given-names></name><name><surname>Troussard</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.</article-title><source>BMC Cancer</source><volume>8</volume><fpage>17</fpage><pub-id pub-id-type="pmid">18208621</pub-id></mixed-citation></ref><ref id="pone.0007314-Esteller1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>JM</given-names></name><name><surname>Dominguez</surname><given-names>G</given-names></name><name><surname>Bonilla</surname><given-names>F</given-names></name><name><surname>Matias-Guiu</surname><given-names>X</given-names></name><etal/></person-group><year>2000</year><article-title>Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.</article-title><source>J Natl Cancer Inst</source><volume>92</volume><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">10749912</pub-id></mixed-citation></ref><ref id="pone.0007314-Pal1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>T</given-names></name><name><surname>Permuth-Wey</surname><given-names>J</given-names></name><name><surname>Betts</surname><given-names>JA</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Fiorica</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.</article-title><source>Cancer</source><volume>104</volume><fpage>2807</fpage><lpage>2816</lpage><pub-id pub-id-type="pmid">16284991</pub-id></mixed-citation></ref><ref id="pone.0007314-Thrall1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrall</surname><given-names>M</given-names></name><name><surname>Gallion</surname><given-names>HH</given-names></name><name><surname>Kryscio</surname><given-names>R</given-names></name><name><surname>Kapali</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>DK</given-names></name><etal/></person-group><year>2006</year><article-title>BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.</article-title><source>Int J Gynecol Cancer</source><volume>16</volume><issue>Suppl 1</issue><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">16515585</pub-id></mixed-citation></ref><ref id="pone.0007314-Singer1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>G</given-names></name><name><surname>Stohr</surname><given-names>R</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Dehari</surname><given-names>R</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.</article-title><source>Am J Surg Pathol</source><volume>29</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">15644779</pub-id></mixed-citation></ref><ref id="pone.0007314-Kupryjanczyk1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Thor</surname><given-names>AD</given-names></name><name><surname>Beauchamp</surname><given-names>R</given-names></name><name><surname>Merritt</surname><given-names>V</given-names></name><name><surname>Edgerton</surname><given-names>SM</given-names></name><etal/></person-group><year>1993</year><article-title>p53 gene mutations and protein accumulation in human ovarian cancer.</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><fpage>4961</fpage><lpage>4965</lpage><pub-id pub-id-type="pmid">8506342</pub-id></mixed-citation></ref><ref id="pone.0007314-Milner1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milner</surname><given-names>BJ</given-names></name><name><surname>Allan</surname><given-names>LA</given-names></name><name><surname>Eccles</surname><given-names>DM</given-names></name><name><surname>Kitchener</surname><given-names>HC</given-names></name><name><surname>Leonard</surname><given-names>RC</given-names></name><etal/></person-group><year>1993</year><article-title>p53 mutation is a common genetic event in ovarian carcinoma.</article-title><source>Cancer Res</source><volume>53</volume><fpage>2128</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">8481915</pub-id></mixed-citation></ref><ref id="pone.0007314-Crum1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Kindelberger</surname><given-names>D</given-names></name><name><surname>Medeiros</surname><given-names>F</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.</article-title><source>Clin Med Res</source><volume>5</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17456833</pub-id></mixed-citation></ref><ref id="pone.0007314-Crum2"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Ince</surname><given-names>TA</given-names></name><name><surname>Muto</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>The distal fallopian tube: a new model for pelvic serous carcinogenesis.</article-title><source>Curr Opin Obstet Gynecol</source><volume>19</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17218844</pub-id></mixed-citation></ref><ref id="pone.0007314-Salvador1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvador</surname><given-names>S</given-names></name><name><surname>Rempel</surname><given-names>A</given-names></name><name><surname>Soslow</surname><given-names>RA</given-names></name><name><surname>Gilks</surname><given-names>B</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.</article-title><source>Gynecol Oncol</source><volume>110</volume><fpage>408</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">18597838</pub-id></mixed-citation></ref><ref id="pone.0007314-Gregory1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>RI</given-names></name><name><surname>Shiekhattar</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>MicroRNA biogenesis and cancer.</article-title><source>Cancer Res</source><volume>65</volume><fpage>3509</fpage><lpage>3512</lpage><pub-id pub-id-type="pmid">15867338</pub-id></mixed-citation></ref><ref id="pone.0007314-Zhang1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Dahlberg</surname><given-names>JE</given-names></name><name><surname>Tam</surname><given-names>W</given-names></name></person-group><year>2007</year><article-title>MicroRNAs in tumorigenesis: a primer.</article-title><source>Am J Pathol</source><volume>171</volume><fpage>728</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">17724137</pub-id></mixed-citation></ref><ref id="pone.0007314-ValenciaSanchez1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Sanchez</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Control of translation and mRNA degradation by miRNAs and siRNAs.</article-title><source>Genes Dev</source><volume>20</volume><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16510870</pub-id></mixed-citation></ref><ref id="pone.0007314-Calin1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Cimmino</surname><given-names>A</given-names></name><name><surname>Di Leva</surname><given-names>G</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.</article-title><source>N Engl J Med</source><volume>353</volume><fpage>1793</fpage><lpage>1801</lpage><pub-id pub-id-type="pmid">16251535</pub-id></mixed-citation></ref><ref id="pone.0007314-Cho1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>WC</given-names></name></person-group><year>2007</year><article-title>OncomiRs: the discovery and progress of microRNAs in cancers.</article-title><source>Mol Cancer</source><volume>6</volume><fpage>60</fpage><pub-id pub-id-type="pmid">17894887</pub-id></mixed-citation></ref><ref id="pone.0007314-EsquelaKerscher1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquela-Kerscher</surname><given-names>A</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><year>2006</year><article-title>Oncomirs - microRNAs with a role in cancer.</article-title><source>Nat Rev Cancer</source><volume>6</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">16557279</pub-id></mixed-citation></ref><ref id="pone.0007314-Asangani1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Rasheed</surname><given-names>SA</given-names></name><name><surname>Nikolova</surname><given-names>DA</given-names></name><name><surname>Leupold</surname><given-names>JH</given-names></name><name><surname>Colburn</surname><given-names>NH</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.</article-title><source>Oncogene</source></mixed-citation></ref><ref id="pone.0007314-Shen1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Ambrosone</surname><given-names>CB</given-names></name><name><surname>DiCioccio</surname><given-names>RA</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Lele</surname><given-names>SB</given-names></name><etal/></person-group><year>2008</year><article-title>A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.</article-title><source>Carcinogenesis</source><volume>29</volume><fpage>1963</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">18660546</pub-id></mixed-citation></ref><ref id="pone.0007314-Mayr1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>C</given-names></name><name><surname>Hemann</surname><given-names>MT</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year>2007</year><article-title>Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation.</article-title><source>Science</source><volume>315</volume><fpage>1576</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">17322030</pub-id></mixed-citation></ref><ref id="pone.0007314-Meng1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Henson</surname><given-names>R</given-names></name><name><surname>Wehbe-Janek</surname><given-names>H</given-names></name><name><surname>Ghoshal</surname><given-names>K</given-names></name><name><surname>Jacob</surname><given-names>ST</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.</article-title><source>Gastroenterology</source><volume>133</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17681183</pub-id></mixed-citation></ref><ref id="pone.0007314-Sampson1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>VB</given-names></name><name><surname>Rong</surname><given-names>NH</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Aris</surname><given-names>V</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.</article-title><source>Cancer Res</source><volume>67</volume><fpage>9762</fpage><lpage>9770</lpage><pub-id pub-id-type="pmid">17942906</pub-id></mixed-citation></ref><ref id="pone.0007314-Corney1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corney</surname><given-names>DC</given-names></name><name><surname>Nikitin</surname><given-names>AY</given-names></name></person-group><year>2008</year><article-title>MicroRNA and ovarian cancer.</article-title><source>Histol Histopathol</source><volume>23</volume><fpage>1161</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">18581287</pub-id></mixed-citation></ref><ref id="pone.0007314-Dahiya1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahiya</surname><given-names>N</given-names></name><name><surname>Sherman-Baust</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>MicroRNA expression and identification of putative miRNA targets in ovarian cancer.</article-title><source>PLoS ONE</source><volume>3</volume><fpage>e2436</fpage><pub-id pub-id-type="pmid">18560586</pub-id></mixed-citation></ref><ref id="pone.0007314-Iorio1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>MV</given-names></name><name><surname>Visone</surname><given-names>R</given-names></name><name><surname>Di Leva</surname><given-names>G</given-names></name><name><surname>Donati</surname><given-names>V</given-names></name><name><surname>Petrocca</surname><given-names>F</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA signatures in human ovarian cancer.</article-title><source>Cancer Res</source><volume>67</volume><fpage>8699</fpage><lpage>8707</lpage><pub-id pub-id-type="pmid">17875710</pub-id></mixed-citation></ref><ref id="pone.0007314-Nam1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>EJ</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><etal/></person-group><year>2008</year><article-title>MicroRNA expression profiles in serous ovarian carcinoma.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>2690</fpage><lpage>2695</lpage><pub-id pub-id-type="pmid">18451233</pub-id></mixed-citation></ref><ref id="pone.0007314-Yang1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>O'Donnell</surname><given-names>JD</given-names></name><etal/></person-group><year>2008</year><article-title>MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.</article-title><source>Cancer Res</source><volume>68</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">18199536</pub-id></mixed-citation></ref><ref id="pone.0007314-Zhang2"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Greshock</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><fpage>7004</fpage><lpage>7009</lpage><pub-id pub-id-type="pmid">18458333</pub-id></mixed-citation></ref><ref id="pone.0007314-Wyman1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyman</surname><given-names>SK</given-names></name><name><surname>Parkin</surname><given-names>RK</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Fritz</surname><given-names>BR</given-names></name><name><surname>O'Briant</surname><given-names>K</given-names></name><etal/></person-group><year>2009</year><article-title>Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.</article-title><source>PLoS One</source><volume>4</volume><fpage>e5311</fpage><pub-id pub-id-type="pmid">19390579</pub-id></mixed-citation></ref><ref id="pone.0007314-Zorn1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorn</surname><given-names>KK</given-names></name><name><surname>Jazaeri</surname><given-names>AA</given-names></name><name><surname>Awtrey</surname><given-names>CS</given-names></name><name><surname>Gardner</surname><given-names>GJ</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><etal/></person-group><year>2003</year><article-title>Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.</article-title><source>Clin Cancer Res</source><volume>9</volume><fpage>4811</fpage><lpage>4818</lpage><pub-id pub-id-type="pmid">14581352</pub-id></mixed-citation></ref><ref id="pone.0007314-Subramanian1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>Lui</surname><given-names>WO</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Espinosa</surname><given-names>I</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA expression signature of human sarcomas.</article-title><source>Oncogene</source></mixed-citation></ref><ref id="pone.0007314-Landgraf1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landgraf</surname><given-names>P</given-names></name><name><surname>Rusu</surname><given-names>M</given-names></name><name><surname>Sheridan</surname><given-names>R</given-names></name><name><surname>Sewer</surname><given-names>A</given-names></name><name><surname>Iovino</surname><given-names>N</given-names></name><etal/></person-group><year>2007</year><article-title>A mammalian microRNA expression atlas based on small RNA library sequencing.</article-title><source>Cell</source><volume>129</volume><fpage>1401</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">17604727</pub-id></mixed-citation></ref><ref id="pone.0007314-ShihIe1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><year>2004</year><article-title>Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.</article-title><source>Am J Pathol</source><volume>164</volume><fpage>1511</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">15111296</pub-id></mixed-citation></ref><ref id="pone.0007314-Corney2"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corney</surname><given-names>DC</given-names></name><name><surname>Flesken-Nikitin</surname><given-names>A</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Nikitin</surname><given-names>AY</given-names></name></person-group><year>2007</year><article-title>MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.</article-title><source>Cancer Res</source><volume>67</volume><fpage>8433</fpage><lpage>8438</lpage><pub-id pub-id-type="pmid">17823410</pub-id></mixed-citation></ref><ref id="pone.0007314-He1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Xuan</surname><given-names>Z</given-names></name><etal/></person-group><year>2007</year><article-title>A microRNA component of the p53 tumour suppressor network.</article-title><source>Nature</source><volume>447</volume><fpage>1130</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">17554337</pub-id></mixed-citation></ref><ref id="pone.0007314-Hermeking1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermeking</surname><given-names>H</given-names></name></person-group><year>2007</year><article-title>p53 enters the microRNA world.</article-title><source>Cancer Cell</source><volume>12</volume><fpage>414</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">17996645</pub-id></mixed-citation></ref><ref id="pone.0007314-Lu1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Miska</surname><given-names>EA</given-names></name><name><surname>Alvarez-Saavedra</surname><given-names>E</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>MicroRNA expression profiles classify human cancers.</article-title><source>Nature</source><volume>435</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">15944708</pub-id></mixed-citation></ref><ref id="pone.0007314-Kobel1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name></person-group><year>2008</year><article-title>Critical molecular abnormalities in high-grade serous carcinoma of the ovary.</article-title><source>Expert Rev Mol Med</source><volume>10</volume><fpage>e22</fpage><pub-id pub-id-type="pmid">18671886</pub-id></mixed-citation></ref><ref id="pone.0007314-Dubeau1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubeau</surname><given-names>L</given-names></name></person-group><year>2008</year><article-title>The cell of origin of ovarian epithelial tumours.</article-title><source>Lancet Oncol</source><volume>9</volume><fpage>1191</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">19038766</pub-id></mixed-citation></ref><ref id="pone.0007314-Folkins1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkins</surname><given-names>AK</given-names></name><name><surname>Jarboe</surname><given-names>EA</given-names></name><name><surname>Roh</surname><given-names>MH</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name></person-group><year>2009</year><article-title>Precursors to pelvic serous carcinoma and their clinical implications.</article-title><source>Gynecol Oncol</source><volume>113</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">19237187</pub-id></mixed-citation></ref><ref id="pone.0007314-Levanon1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levanon</surname><given-names>K</given-names></name><name><surname>Crum</surname><given-names>C</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name></person-group><year>2008</year><article-title>New insights into the pathogenesis of serous ovarian cancer and its clinical impact.</article-title><source>J Clin Oncol</source><volume>26</volume><fpage>5284</fpage><lpage>5293</lpage><pub-id pub-id-type="pmid">18854563</pub-id></mixed-citation></ref><ref id="pone.0007314-Hirst1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirst</surname><given-names>JE</given-names></name><name><surname>Gard</surname><given-names>GB</given-names></name><name><surname>McIllroy</surname><given-names>K</given-names></name><name><surname>Nevell</surname><given-names>D</given-names></name><name><surname>Field</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.</article-title><source>Int J Gynecol Cancer</source><volume>19</volume><fpage>826</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">19574767</pub-id></mixed-citation></ref><ref id="pone.0007314-Kindelberger1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindelberger</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Feltmate</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.</article-title><source>Am J Surg Pathol</source><volume>31</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">17255760</pub-id></mixed-citation></ref><ref id="pone.0007314-Tong1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>GX</given-names></name><name><surname>Chiriboga</surname><given-names>L</given-names></name><name><surname>Hamele-Bena</surname><given-names>D</given-names></name><name><surname>Borczuk</surname><given-names>AC</given-names></name></person-group><year>2007</year><article-title>Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin?</article-title><source>Mod Pathol</source><volume>20</volume><fpage>856</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">17529925</pub-id></mixed-citation></ref><ref id="pone.0007314-Bandres1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandres</surname><given-names>E</given-names></name><name><surname>Cubedo</surname><given-names>E</given-names></name><name><surname>Agirre</surname><given-names>X</given-names></name><name><surname>Malumbres</surname><given-names>R</given-names></name><name><surname>Zarate</surname><given-names>R</given-names></name><etal/></person-group><year>2006</year><article-title>Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.</article-title><source>Mol Cancer</source><volume>5</volume><fpage>29</fpage><pub-id pub-id-type="pmid">16854228</pub-id></mixed-citation></ref><ref id="pone.0007314-Iorio2"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>MV</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Veronese</surname><given-names>A</given-names></name><name><surname>Spizzo</surname><given-names>R</given-names></name><etal/></person-group><year>2005</year><article-title>MicroRNA gene expression deregulation in human breast cancer.</article-title><source>Cancer Res</source><volume>65</volume><fpage>7065</fpage><lpage>7070</lpage><pub-id pub-id-type="pmid">16103053</pub-id></mixed-citation></ref><ref id="pone.0007314-Michael1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael</surname><given-names>MZ</given-names></name><name><surname>SM</surname><given-names>OC</given-names></name><name><surname>van Holst Pellekaan</surname><given-names>NG</given-names></name><name><surname>Young</surname><given-names>GP</given-names></name><name><surname>James</surname><given-names>RJ</given-names></name></person-group><year>2003</year><article-title>Reduced accumulation of specific microRNAs in colorectal neoplasia.</article-title><source>Mol Cancer Res</source><volume>1</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">14573789</pub-id></mixed-citation></ref><ref id="pone.0007314-Ozen1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozen</surname><given-names>M</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Ozdemir</surname><given-names>M</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Widespread deregulation of microRNA expression in human prostate cancer.</article-title><source>Oncogene</source></mixed-citation></ref><ref id="pone.0007314-Akao1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akao</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Kitade</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><year>2007</year><article-title>Downregulation of microRNAs-143 and -145 in B-cell malignancies.</article-title><source>Cancer Sci</source><volume>98</volume><fpage>1914</fpage><lpage>1920</lpage><pub-id pub-id-type="pmid">17892514</pub-id></mixed-citation></ref><ref id="pone.0007314-Akao2"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akao</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><year>2006</year><article-title>MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers.</article-title><source>Oncol Rep</source><volume>16</volume><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">16969504</pub-id></mixed-citation></ref><ref id="pone.0007314-Gilks1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Vanderhyden</surname><given-names>BC</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Longacre</surname><given-names>TA</given-names></name></person-group><year>2005</year><article-title>Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.</article-title><source>Gynecol Oncol</source><volume>96</volume><fpage>684</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">15721412</pub-id></mixed-citation></ref><ref id="pone.0007314-He2"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group><year>2007</year><article-title>microRNAs join the p53 network&#x02013;another piece in the tumour-suppression puzzle.</article-title><source>Nat Rev Cancer</source><volume>7</volume><fpage>819</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">17914404</pub-id></mixed-citation></ref><ref id="pone.0007314-ONeill1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>CJ</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Malpica</surname><given-names>A</given-names></name><name><surname>Foster</surname><given-names>H</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name></person-group><year>2005</year><article-title>An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.</article-title><source>Am J Surg Pathol</source><volume>29</volume><fpage>1034</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">16006797</pub-id></mixed-citation></ref><ref id="pone.0007314-Chuaqui1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuaqui</surname><given-names>RF</given-names></name><name><surname>Bonner</surname><given-names>RF</given-names></name><name><surname>Best</surname><given-names>CJ</given-names></name><name><surname>Gillespie</surname><given-names>JW</given-names></name><name><surname>Flaig</surname><given-names>MJ</given-names></name><etal/></person-group><year>2002</year><article-title>Post-analysis follow-up and validation of microarray experiments.</article-title><source>Nat Genet 32 Suppl</source><fpage>509</fpage><lpage>514</lpage></mixed-citation></ref><ref id="pone.0007314-Etienne1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etienne</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>MH</given-names></name><name><surname>Peppers</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>RA</given-names><suffix>Jr</suffix></name></person-group><year>2004</year><article-title>Comparison of mRNA gene expression by RT-PCR and DNA microarray.</article-title><source>Biotechniques</source><volume>36</volume><fpage>618</fpage><lpage>620, 622, 624&#x02013;616</lpage><pub-id pub-id-type="pmid">15088380</pub-id></mixed-citation></ref><ref id="pone.0007314-Morey1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morey</surname><given-names>JS</given-names></name><name><surname>Ryan</surname><given-names>JC</given-names></name><name><surname>Van Dolah</surname><given-names>FM</given-names></name></person-group><year>2006</year><article-title>Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR.</article-title><source>Biol Proced Online</source><volume>8</volume><fpage>175</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">17242735</pub-id></mixed-citation></ref><ref id="pone.0007314-Sherlock1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Kasarskis</surname><given-names>A</given-names></name><name><surname>Binkley</surname><given-names>G</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><etal/></person-group><year>2001</year><article-title>The Stanford Microarray Database.</article-title><source>Nucleic Acids Res</source><volume>29</volume><fpage>152</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">11125075</pub-id></mixed-citation></ref><ref id="pone.0007314-Eisen1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><year>1998</year><article-title>Cluster analysis and display of genome-wide expression patterns.</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><fpage>14863</fpage><lpage>14868</lpage><pub-id pub-id-type="pmid">9843981</pub-id></mixed-citation></ref><ref id="pone.0007314-Tusher1"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tusher</surname><given-names>VG</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name></person-group><year>2001</year><article-title>Significance analysis of microarrays applied to the ionizing radiation response.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>5116</fpage><lpage>5121</lpage><pub-id pub-id-type="pmid">11309499</pub-id></mixed-citation></ref><ref id="pone.0007314-Lewis1"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year>2005</year><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.</article-title><source>Cell</source><volume>120</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15652477</pub-id></mixed-citation></ref><ref id="pone.0007314-Grimson1"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><etal/></person-group><year>2007</year><article-title>MicroRNA targeting specificity in mammals: determinants beyond seed pairing.</article-title><source>Mol Cell</source><volume>27</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">17612493</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study is funded by the National Cancer Institute of Canada (#017051) and the Michael Smith Foundation for Health Research Unit Grant (#INRUA006045). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>